My Stansberry Research Pro Trader subscribers made a lot of money last week. We closed a call-option trade on pharmaceutical giant Pfizer (PFE) for a 214% gain in just one week in my Direct Line service. In the official Pro Trader portfolio, we booked profits of 18.3% in one month on biotech juggernaut Bristol-Myers Squibb (BMY) and 22% in one day on Pfizer (PFE). We also recorded a loss of about 15% on a put-option trade on Brazil's stock market with the iShares MSCI Brazil Capped Fund (EWZ). But I consider that a small victory, since the position traded at a loss of almost 90% one week before that. And we could have done even better. If we had held these positions just one day longer, they all would have been even more profitable. That's not necessarily true today, though. Some of the trades are better off. Most are worse off. And that got me thinking about how to describe my profit-taking philosophy.
Top 5 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month’s Gain
Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
Transenterix Inc. (NYSE: TRXC) $3.46 77.84%
While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
- [By Dan Caplinger]
Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here’s why they did so well.
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
- [By Logan Wallace]
BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.
A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.
Top 5 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. Specifically, the agency approved Prolia (denosumab), driven by positive late-stage results.
- [By ]
Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.
- [By ]
This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV) , Amgen (AMGN) , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN) and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 10.24 million shares from the previous level of 10.63 million. Shares were last seen trading at $206.00, in a 52-week trading range of $163.31 to $210.19.
- [By Keith Speights]
The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.
- [By Joseph Griffin]
South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.
Top 5 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)
- [By Benzinga News Desk]
A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link
Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
The pending home sales index for April will be released at 10:00 a.m. ET.
The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
- [By Lisa Levin] Companies Reporting Before The Bell
United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion.
The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion.
Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion.
Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion.
Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion.
The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion.
Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion.
3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion.
JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion.
Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion.
Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion.
Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion.
Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion.
The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion.
Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion.
PACCAR Inc (NASDAQ: PCAR) is projected to
- [By Brian Orelli]
Data source: Ionis Pharmaceuticals.
What happened with Ionis Pharmaceuticals this quarter?
Revenue increased thanks to $41 million in royalties from Biogen’s (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis’ financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.
Image source: Getty Images.
- [By Stephan Byrd]
Traders bought shares of Biogen Inc (NASDAQ:BIIB) on weakness during trading on Tuesday. $119.44 million flowed into the stock on the tick-up and $86.88 million flowed out of the stock on the tick-down, for a money net flow of $32.56 million into the stock. Of all companies tracked, Biogen had the 26th highest net in-flow for the day. Biogen traded down ($7.15) for the day and closed at $345.41
- [By Joseph Griffin]
Rhenman & Partners Asset Management AB lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 130.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company’s stock after purchasing an additional 17,000 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Biogen were worth $10,599,000 as of its most recent filing with the Securities and Exchange Commission.
- [By Chris Hill]
In this episode of Motley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS) finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health (NYSE:CVS) diversifies into CBD lotion. Levi Strauss (NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE) sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s (NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.
Top 5 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Keith Speights]
Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiran appears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.
- [By Ethan Ryder]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.
- [By Shane Hupp]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now. However, In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release.”
- [By Brian Orelli]
Following the Food and Drug Administration (FDA) approval of Onpattro, Alnylam Pharmaceuticals’ (NASDAQ:ALNY) first drug to treat hereditary transthyretin-mediated amyloidosis (hATTR), the biotech held a conference call to go over the plan for launch. Here are three things management wants investors to know: